Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?
- 01.08.2017
- Brief Report
Erschienen in:
- Verfasst von
-
Arti R. Jonna
Korrespondierender Autor Arti R. Jonna
- Department of Breast Radiology, Baylor College of Medicine, 77030, Houston, USA
- Breast Imaging Fellow, Baylor College of Medicine, 77401, Bellaire, USA
-
Kenny Q. Sam
Kenny Q. Sam
- Department of Breast Radiology, Baylor College of Medicine, 77030, Houston, USA
-
Lilian O. Ebuoma
Lilian O. Ebuoma
- Department of Breast Radiology, Baylor College of Medicine, 77030, Houston, USA
-
Emily L. Sedgwick
Emily L. Sedgwick
- Department of Breast Radiology, Baylor College of Medicine, 77030, Houston, USA
-
Tao Wang
Tao Wang
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, 77030, Houston, USA
-
Ana P. Benveniste
Ana P. Benveniste
- Department of Breast Radiology, Baylor College of Medicine, 77030, Houston, USA
- Erschienen in
- Breast Cancer Research and Treatment | Ausgabe 2/2017
Abstract
Purpose
The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician’s decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralateral disease, which may change surgical or medical management. Our purpose was to compare the four main breast cancer subtypes in our patient population (i.e., luminal A, luminal B, HER2 enriched and triple-negative) who underwent pretreatment staging MRIs to determine whether certain breast cancer subtypes are more likely to have multicentric or contralateral disease.
Methods
We retrospectively reviewed 435 patients with biopsy-proven invasive breast cancer who had staging MRI.
Results
Of these patients, 14 had biopsy-proven multicentric disease (3.2% of total) and 15 had biopsy-proven contralateral second tumor sites (3.4% of total). There was no statistically significant difference between primary tumor subtype and likelihood of multicentric or contralateral disease (p = 0.3065).
Conclusion
Pretreatment staging MRI can detect multicentric and/or contralateral additional tumor sites, which ultimately changes staging, treatment options, and outcomes for patients with biopsy-proven breast cancer. There is no correlation between primary breast cancer subtype and likelihood of multicentric or contralateral disease.
Anzeige
- Titel
- Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?
- Verfasst von
-
Arti R. Jonna
Kenny Q. Sam
Lilian O. Ebuoma
Emily L. Sedgwick
Tao Wang
Ana P. Benveniste
- Publikationsdatum
- 01.08.2017
- Verlag
- Springer US
- Erschienen in
-
Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217 - DOI
- https://doi.org/10.1007/s10549-017-4426-y
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
